Related Experiment Video
Updated: Dec 24, 2025
Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
Published on: April 18, 2025
Resveratrol and Diabetic Cardiomyopathy: Focusing on the Protective Signaling Mechanisms
Yan-Jun Song1, Chong-Bin Zhong2, Wei Wu1
1Department of Cardiology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Science, 1 Shuai Fu Yuan, Beijing 100730, China.
Insights
Resveratrol (RSV) protects against diabetic cardiomyopathy (DCM) by targeting key mediators like Sirtuins and AMP-activated kinase. This natural compound offers a promising therapeutic strategy for diabetic heart disease.
Area of Science:
- Cardiology
- Endocrinology
- Pharmacology
Background:
- Diabetic cardiomyopathy (DCM) is a serious cardiovascular complication of diabetes mellitus, leading to diastolic dysfunction and heart failure.
- DCM is a significant cause of mortality in diabetic patients.
- Resveratrol (RSV), a natural stilbene, exhibits known cardioprotective effects in various heart conditions.
Purpose of the Study:
- To elucidate the specific roles of Resveratrol (RSV) in the prevention and treatment of diabetic cardiomyopathy (DCM).
- To review the downstream targets of RSV involved in cardioprotection under hyperglycemic conditions.
Main Methods:
- Review of in vivo and in vitro studies examining the effects of RSV on DCM.
- Analysis of signaling pathways and molecular targets modulated by RSV.
Main Results:
- RSV activates key cardioprotective mediators, including Sirtuins 1/3 and AMP-activated kinase, in response to hyperglycemia.
- RSV regulates other signaling molecules, such as forkhead box-O3a and extracellular regulated protein kinases.
- RSV demonstrates beneficial effects by counteracting oxidative stress, inflammation, and apoptosis in high-glucose exposed cardiomyocytes.
Conclusions:
- Resveratrol (RSV) shows significant potential in preventing and treating diabetic cardiomyopathy (DCM) through its modulation of key molecular targets.
- Combination therapy with RSV and stem cells presents a promising future strategy for DCM management.
Abstract:
Diabetic cardiomyopathy (DCM) is a common cardiovascular complication of diabetic mellitus that is characterized by diastolic disorder in the early stage and clinical heart failure in the later stage. Presently, DCM is considered one of the major causes of death in diabetic patients. Resveratrol (RSV), a naturally occurring stilbene, is widely reported as a cardioprotective substance in many heart diseases. Thus far, the specific roles of RSV in DCM prevention and treatment have attracted great attention. Here, we discuss the roles of RSV in DCM by focusing its downstream targets from both in vivo and in vitro studies. Among such targets, Sirtuins 1/3 and AMP-activated kinase have been identified as key mediators that induce cardioprotection during hyperglycemia. In addition, many other signaling molecules (e.g., forkhead box-O3a and extracellular regulated protein kinases) are also regulated in the presence of RSV and exert beneficial effects such as opposing oxidative stress, inflammation, and apoptosis in cardiomyocytes exposed to high-glucose conditions. The beneficial potential of an RSV/stem cell cotherapy is also reviewed as a promising therapeutic strategy for preventing the development of DCM.
Related Concept Videos
01:29Cardiomyopathy IV: Restrictive Cardiomyopathy
01:28Insulin: The Receptor and Signaling Pathways
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:30Coronary Artery Disease I: Introduction